Neuren Closer to Phase 2 Testing of NNZ-2591 After FDA Guidance

Neuren Closer to Phase 2 Testing of NNZ-2591 After FDA Guidance

297485

Neuren Closer to Phase 2 Testing of NNZ-2591 After FDA Guidance

Neuren Pharmaceuticals is a step closer to Phase 2 clinical testing of NNZ-2591, its investigational therapy for Angelman syndrome, Phelan–McDermid syndrome, and Pitt Hopkins syndrome, after the company received clear and constructive guidance from the U.S. Food and Drug Administration. All three syndromes are early childhood, genetic neurodevelopmental disorders for which there are currently no approved treatments. The positive feedback from the FDA’s Office of Neuroscience means Neuren can proceed with investigational new drug (IND)…

You must be logged in to read/download the full post.